in a sterile preparation, my query is on criteria for assessing the need of excluding
1) "Microbial Limit test" (MLT) (in-addition-to test for sterility )
2) BET test(BET) ,( considering that input materials are controlled, and process is qualified (media fill, area qualification etc),
can we invoke, Microbial Contamination Risk Level of Compounded sterile preparations (CSPs) of USP <797> PHARMACEUTICAL COMPOUNDING?STERILE PREPARATIONS for excluding MLT & BET
In-fact for some of the USP monographs of "sterile water for injection", do not contain tests for microbial limit tests.
BUT, there is indirect reference for inclusion of Microbial limit test, but not specific and exact references.
* * * *
1) "Microbial Limit test" (MLT) (in-addition-to test for sterility )
2) BET test(BET) ,( considering that input materials are controlled, and process is qualified (media fill, area qualification etc),
can we invoke, Microbial Contamination Risk Level of Compounded sterile preparations (CSPs) of USP <797> PHARMACEUTICAL COMPOUNDING?STERILE PREPARATIONS for excluding MLT & BET
In-fact for some of the USP monographs of "sterile water for injection", do not contain tests for microbial limit tests.
BUT, there is indirect reference for inclusion of Microbial limit test, but not specific and exact references.
* * * *
* * * *https://www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol4/pdf/CFR-2011-title21-vol4-sec200-51.pdf
? 200.51 Aqueous-based drug products for oral inhalation.
(a) All aqueous-based drug products for oral inhalation must be manufactured to be sterile.
(b) Manufacturers must also comply with the requirements in ? 211.113(b) of this chapter.
[65 FR 34089, May 26, 2000]
* * * *
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=211.113
Sec. 211.113 Control of microbiological contamination.
(a) Appropriate written procedures, designed to prevent objectionable microorganisms in drug products not required to be sterile, shall be established and followed.
(b) Appropriate written procedures, designed to prevent microbiological contamination of drug products purporting to be sterile, shall be established and followed. Such procedures shall include validation of all aseptic and sterilization processes.
[43 FR 45077, Sept. 29, 1978, as amended at 73 FR 51932, Sept. 8, 2008]
Last edited: